 "Covid-19: Wockhardt to manufacture, supply Sputnik V, Sputnik Light vaccine")
Wockhardt has entered into an agreement with Dubai-based Enso Healthcare DMCC and Human Vaccine (HV) LLC, a wholly-owned subsidiary of the Russian Direct Investment Fund, for the manufacture and supply of the Sputnik V and Sputnik Light vaccine against Covid-19, the pharmaceutical company said in a statement on Friday.
Wockhardt will supply up to 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine to Enso "subject to requisite approvals", it said.
"Subject to requisite approvals and other conditions, upon successful technology transfer from HV to the company, the company will manufacture and supply to Enso upto 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine against Covid-19,'' Wockhardt said in a statement.
The agreement between the Company, HV, Enso was reached under the aegis of Enso, RDIF's co-ordination partner for sourcing Sputnik vaccine in India.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%